Understanding Age-Related Macular Degeneration (AMD) and Its Treatment

Age-related macular degeneration (AMD) is a degenerative eye condition that impacts central vision. It is one of the primary causes of eyesight loss in older persons. Understanding the risks to your vision and seeking treatment as appropriate will help you manage the condition and keep your sight.

AMD is caused by age-related degeneration of the macular, the central region of the retina responsible for clear vision. When this happens, central vision can become blurry, wavy, or distorted. (Central vision helps you see what's right before you.) Other symptoms, such as blind spots or missing eyesight, may also appear.

Macular degeneration does not impair peripheral vision. It might affect one or both eyes.

AMD eye illness can disrupt your life in a variety of ways. It can influence your ability to read, drive, and conduct other daily activities. If the condition continues at an advanced stage, there may be a significant loss of central vision.

Types of Age-Related Macular Degeneration

There are two forms of age-related macular degeneration (AMD): dry (atrophic) and wet (neovascular).

Dry AMD

The majority of people with AMD have dry AMD (also known as atrophic AMD), which occurs when the macula thins with age. Dry AMD occurs in three stages: early, middle, and late. It normally progresses gradually over several years. There is no treatment for late dry AMD; however, you can maximize your remaining vision. If you have late dry AMD in only one eye, you can take action to protect the other.

Stages of Dry AMD

Early AMD: Drusen are tiny and scarce in numerous. There is typically no vision loss.
Intermediate AMD: Drusen grow more extensive and more frequent, with possible pigment alterations in the retina. Some visual loss may occur, but it is often minimal.
Advanced dry AMD (Geographic Atrophy): Macular degeneration causes substantial vision loss. This stage involves the disintegration of retinal cells and supporting tissue.

Wet AMD

Wet AMD, also known as advanced neovascular AMD, is a rare late AMD that typically causes rapid vision loss. Any stage of dry AMD can progress to wet AMD, but wet AMD is always a late stage. It occurs when aberrant blood vessels form in the rear of the eye, damaging the macula. The good news is that there are treatments available for wet AMD.

Symptoms of AMD

The symptoms of AMD vary according to the kind and stage of the illness. Early stages of AMD may not produce any visible symptoms. However, when the condition advances, the following symptoms may develop:

Blurry or distorted vision: Straight lines may appear wavy, while shapes may appear distorted.
Dark or empty areas in the central vision make it difficult to read or recognize and recognize faces.
Colour Perception: Colors may appear less brilliant or vibrant.
Slow Vision Recovery Following Exposure to Bright Light: Difficulty responding to changes in lighting conditions.

How widespread is macular degeneration?

Almost 20 million persons in the United States suffer from macular degeneration. Globally, it is estimated that 288 million people will have the illness by 2040.

In the United States, macular degeneration is the leading cause of visual loss among adults aged 60 and older.

Am I at risk for AMD?

Am I at risk of developing AMD?

As you age, your chance of AMD increases.AMD is more common in individuals over 55 years old.AMD risk is also greater for persons who:

Have a family history of Alzheimer'sAlzheimer's disease
Are Caucasian
Smokers

Regular eye exams are crucial for those at risk of AMD due to age, family history, or other causes. Consult your doctor about how frequently you should have them. Early AMD has no symptoms, so don't wait for your vision to change!

Risk factors for AMD

Several factors may raise the risk of acquiring AMD:

Individuals above the age of 60 have a much higher risk.

Genetics: A family history of AMD increases the risk of illness.
AMD is more prevalent in Caucasians.
Smoking is a substantial risk factor for AMD, increasing the likelihood of acquiring it by twofold.
Obesity and Poor Diet: Poor nutrition and a high-fat diet can contribute to AMD development.
Cardiovascular Disease: Conditions affecting the heart and blood vessels can raise risk.

Diagnosing AMD

Diagnosing AMD requires a thorough eye examination that includes the following steps:

Visual acuity test: Determines how well a person sees at different distances.
A dilated eye exam allows an eye care expert to examine the retina and macula with powerful magnification lenses.
The Amsler Grid is a method for detecting visual issues associated with macular degeneration.
Optical Coherence Tomography (OCT): Produces comprehensive images of the retina, revealing areas of thinning, thickening, and fluid buildup.
Fluorescein Angiography: This procedure involves injecting a dye into the circulation to highlight blood vessels in the retina.

Treatment options for AMD

While there is no cure for AMD, some therapies can help slow its growth and improve eyesight. The treatment technique varies depending on the kind and stage of AMD.

Treatment for dry AMD

Nutritional supplements

Studies, such as the Age-Related Eye Disease Study (AREDS) and AREDS2, have demonstrated that high-dose vitamin and mineral supplements can reduce the likelihood of advancement in people with intermediate or advanced dry AMD. The recommended formulation contains:

Vitamin C (500mg)
Vitamin E (400 IU).
Zinc (80mg)
Copper (2mg)
Lutein (10 mg) Zeaxanthin (2 mg).

Lifestyle Modifications

Maintaining a healthy lifestyle can help manage AMD. Recommendations include

Quitting smoking reduces the risk of AMD development.
A healthy diet should consist of leafy green vegetables, omega-3-rich fish, and a low-fat diet.
Regular exercise promotes general health and can improve eye health.
Wearing UV-protective sunglasses can help protect the eyes.

Treatment for Wet AMD

Anti-VEGF therapy

The primary treatment for wet AMD is anti-vascular endothelial growth factor (anti-VEGF) injections. These medications prevent aberrant blood vessel formation and minimize fluid leakage. The most common anti-VEGF medicines are:

Lucentis (ranibizumab) – In 2006, the FDA authorized authorized Lucentis (ranibizumab) to treat age-related macular degeneration. It is given once a month to the afflicted eye.
Avastin (bevacizumab) –Since 2005, Avastin (bevacizumab) has been used "off-label" to treat wet AMD despite being FDA-approved for other cancer treatments. Macular degeneration injections are usually administered every four to six weeks. However, the dose regimen may vary depending on individual demands.
In 2011, the FDA authorized Eylea HD (aflibercept), commonly known as "VEGF trap-eye," to treat wet AMD. In August 2023, the FDA approved Eylea HD (a newer, higher-dose regimen). The first three doses are given to the afflicted eye once a month. Additional shots are administered every two to four months.
Vabysmo (faricimab-svoa) obtained FDA approval for treating wet AMD in January 2022. For the first four doses, it is administered as an eye injection once a month. After the initial four-dose regimen, imaging techniques, including optical coherence tomography and visual acuity examinations, are performed after eight and twelve weeks. The findings of these checks are used to decide how often future doses should be administered.
Beovu (brolucizumab-dbll) obtained FDA approval for treating wet AMD in October 2019. This macular degeneration medicine is given once a month for the first three months. Follow-up doses are administered every two to three months.

Biosimilar anti-VEGF medicines can treat wet AMD. A biosimilar medication is similar to the product's original or brand-name version. In contrast, a generic drug is a chemically identical clone of the original substance.

Like the original form, a biosimilar must be tested and approved by the FDA, which can be costly. However, part of the original testing data can be used to create a biosimilar. This implies that they can frequently be produced more rapidly and at a lower cost, which may provide cost reductions to some patients.

The FDA has approved two biosimilar anti-VEGF medicines for treating wet AMD. It includes:

The FDA approved Byooviz (a ranibizumab biosimilar) in September 2021. It is administered as a monthly eye injection.
The FDA approved Cimerli (ranibizumab biosimilar) in August 2022. It is also administered as an eye injection once a month.

Photodynamic Therapy (PDT)

Photodynamic therapy (PDT) uses a combination of a low-intensity laser and the medication Visudyne (verteporfin) to treat macular degeneration. In cases of wet AMD, it aims to seal off aberrant blood vessels leaking into the macula. In 2000, the FDA approved PDT.

During this procedure, a light-sensitive medication called Visudyne is injected intravenously into the arm. The medicine reaches the eye's blood vessels through the circulatory system. The next step is using a specialized eye drop to numb the eye. The medication is activated by projecting a laser into the back of the eye through a contact lens that is placed on the eye. Clots grow in the aberrant arteries and seal them off as a result of this process.

The increased use of anti-VEFG medication has led to a decrease in the frequency of PDT. On the other hand, it can be used alongside anti-VEFG injections.

Laser Surgery

Sometimes, aberrant blood vessels can be destroyed with a high-energy laser beam. However, this technique is less frequently used because it risks harming nearby healthy tissue and better alternatives, such as anti-VEFG therapy, are available.

Modern therapies and studies

Treatment research for AMD is continuing, and researchers are looking into numerous potential avenues:

Retinal gene therapy is inserting new genes into the retina to either repair damaged genes or add new functions to fight AMD.
Stem cell therapy: Scientists are investigating the possibility of using stem cells to repair missing or damaged retinal cells and restore patients' eyesight.
Implants designed to stimulate the optic nerve or retina directly can help people regain their sight.
Medications in Development: Researchers are seeking to improve the efficacy and convenience of AMD treatments as they develop various new medications and drug delivery technologies.

Living with AMD

Living with AMD can be challenging, but several strategies and resources can help individuals maintain their quality of life:

Managing AMD

Though it may be difficult, there are several tools and resources available to help people with AMD live their best lives:

Assistance for People with Low Vision Tools

To improve what little vision a person has and to aid with everyday tasks, low-vision devices are available. Some examples are:

Reading tiny print is made easier with the use of magnifying glasses.
For tasks requiring long-distance vision, reading telescopes can be attached to eyeglasses.
Electronic magnifiers allow you to change the contrast and increase the magnification.

Restoring good eye-vision

People who have experienced visual loss might get assistance and training through vision rehabilitation programs. Potential services may encompass:

Individuals can learn to safely traverse their surroundings with the aid of orientation and mobility training.
Training in using assistive technology and non-visual cues is an example of an adaptive technique.
Psychological Assistance: Talk therapy to help you deal with the mental and emotional effects of blindness.

Keeping AMD at Bay

It is not possible to avoid AMD altogether. However, you can lower your risk by making some changes to your lifestyle:

Managing and slowing the progression of AMD can be achieved through early identification through routine eye check-ups.
Maintain Good Eye Health with a Diet Heavy in Omega-3 Fatty Acids and Produce.
One of the most important things you can do to lower your risk of AMD is to quit smoking.
Wearing sunglasses with UV protection helps shield your eyes from harmful sun rays.
Reducing the risk of age-related macular degeneration (AMD) is possible by managing preexisting health issues.

What can I do if AMD causes my vision to deteriorate?

Neither late AMD nor bilateral AMD affects all people with AMD. However, if you are diagnosed with AMD, you may find it difficult to live with visual loss. Everyday chores become more challenging for those with impaired vision, even with the help of corrective lenses, medication, or surgery.

There are solutions, nevertheless, such as low vision aids and vision rehabilitation programs. If you have limited vision, vision rehabilitation can teach you how to live independently and participate in daily activities.

Conclusion

One of the leading causes of visual loss in the elderly is age-related macular degeneration. To effectively manage the condition, one must be knowledgeable about the various forms, symptoms, risk factors, and available therapies. There is currently no known way to reverse age-related macular degeneration (AMD), but the good news is that the disease can be managed with early diagnosis and therapy. New medicines are being investigated in ongoing research, promising better management of this challenging condition. Despite the difficulties of vision loss, people with AMD can live fulfilling lives with the help of medical interventions, lifestyle changes, and support services.

Casey Optical Too, LLC, offers a warm and comprehensive environment that addresses all your eye care needs. We invite you to schedule an appointment with one of our top optometrists and experience the difference for yourself. Your vision is our priority, and we are dedicated to serving our community with excellence.

Next Post Previous Post